Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

Официальное название

A Double-blind, Randomised, 30-week Placebo-controlled Phase IV Study to Assess the Efficacy and Safety of Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

Обзор

Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.

Вмешательства

• Препарат Osilodrostat
  Osilodrostat tablets 1 mg and 5 mg for oral useOsilodrostat tablets 1 mg and 5 mg for oral use.During the 18-week titration phase, the dose of the medication will be titrated every 3 weeks based on the cortisolaemic and clinical response to treatment. An independent endocrinologist titration committee will be applied to provide recommendations on dose-titration based on biochemical and clinical response. At the end of the 18-week dose titration phase, participants will enter a 12-week dose maint
• Препарат Placebo
  matching placebo

Первичные конечные точки

• To evaluate the efficacy of osilodrostat on the proportion of participants with normalisation of urinary-free cortisol (UFC) [Срок оценки: 30 weeks]

Критерии участия

Критерии включения

• Male or female ≥ 18 years of age
• Able to provide and have provided signed written informed consent prior to study participation
• Diagnosis of endogenous Cushing's Syndrome
• mUFC values from two 24h urinary collections > ULN and ≤ 2x ULN
• Participants with uncontrolled hypertension on stable doses of BP lowering medications (for at least 4 weeks); qualifying BP measurements by ABPM taken prior to randomisation defined as: Average of 24h ABPM SBP ≥ 135 or DBP ≥ 85 mmHg
• Participants under glucocorticoid replacement therapy can be recruited only if this therapy has been already stopped for at least seven days or 5 half-lives prior to screening, whichever was longer
• Not taking any drug therapy for CS. The following minimum periods without these medications need to be completed before baseline assessments:

• Steroidogenesis inhibitors (e.g. ketoconazole, metyrapone): 1 week
• Mifepristone: 3 weeks
• SC Pasireotide: 1 week
• Pasireotide LAR: 3 months
• Cabergoline: 4 weeks
• Able to take oral medication and be willing to comply with the requirements of the study

Критерии исключения

• Previously treated with osilodrostat less than 12 weeks prior to start of screening
• Known hypersensitivity to osilodrostat
• Presence of any severe and/or uncontrolled medical condition or other conditions that could affect participation in the study
• Participants who are scheduled for a surgery to treat CS within 32 weeks of randomisation to the study drug
• Presence of a known "long term" history of both hypertension and diabetes (defined as both hypertension and diabetes diagnosed >10 years prior to the initial diagnosis of endogenous CS)
• History of cyclic Cushing's Syndrome with fluctuating clinical manifestations
• Participants with pseudo-CS
• Participants with compression of the optic chiasm due to a macroadenoma or participants at high risk of compression of the optic chiasm (tumour within 2 mm of optic chiasm)
• Pituitary radiation therapy within 3 years of screening
• Ectopic ACTH syndrome or adrenocortical carcinoma with a life expectancy of <3 years or receiving chemotherapy
• Having received prior mitotane treatment
• Participants who are shift workers or have conditions that can affect the measurement of late night salivary cortisol (LNSC) or the LDDST
• Poorly controlled diabetes mellitus with a baseline HbA1c > 10.5%
• Poorly controlled BP defined as: Average SBP ≥ 170 or average DBP ≥ 110 mmHg as measured by the 24h ABPM
• Participants who are hypothyroid and not on adequate replacement therapy
• History of major surgery/surgical therapy for any cause within 1 month before entering the study.
• Presence of bradycardia and/or QT-related exclusion criteria
• Total bilirubin > 1.5 x ULN and ALT or AST > 3 x ULN
• Participation in any clinical investigation within 4 weeks prior to screening or longer if required by local regulation (Use of an investigational drug within 1 month prior to dosing)
• Occurrence of any significant acute illness within the three weeks prior to dosing/randomisation
• Female participants who are pregnant, intending to become pregnant or breastfeed during the study or lactating, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
• Women of childbearing potential (WOCBP) who are unwilling to use highly effective contraception methods
• Potentially unreliable or vulnerable participants (e.g. person kept in detention) and those judged by the Investigator to be unsuitable for the study

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Тройное слепое

Основная цель

Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07247162 · LCI699-RECAG-CL-0615 · 2025-524649-28-00

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗